International Journal of Multidisciplinary Research and Growth Evaluation.

Predictive Analytics in Drug Discovery, Disease Monitoring, and Mycology

Vanna Kashetu Alasa [1], Kaddu Alasa [2], Diana Karim [1*]

[1] Department of Computer Science, Yaba College of Technology, Lagos, Nigeria

[2] Department of Biological Science, Yaba College of Technology, Lagos, Nigeria

* Corresponding Author: **Diana Karim**

Article Info

ISSN (online): 2582-7138
Volume: 03
Issue: 02
March-April 2022
Received: 15-03-2022
Accepted: 18-04-2022
Page No: 825-830

Abstract

The convergence of big data, machine learning (ML), and artificial intelligence (AI) has catalyzed a paradigm shift across biomedical and ecological sciences. This review explores the transformative role of predictive analytics in three interlinked domains: drug discovery, disease monitoring, and mycology. In drug development, predictive tools have accelerated the identification of promising compounds, optimized lead selection, and improved toxicity forecasting dramatically reducing cost and time. Deep learning architecture and graph-based models are now routinely used to design novel therapeutics and screen compound libraries with high precision. Mycology, though historically underrepresented in computational biology, is gaining from predictive analytics through automated fungal classification, ecological trait modeling, and biosurveillance applications. Advances in image-based recognition and genomic trait prediction are fostering new avenues for fungal biodiversity research and natural product discovery. Despite these achievements, challenges persist ranging from data heterogeneity and model interpretability to regulatory constraints and ethical considerations. This review outlines current limitations and proposes a roadmap for integrating multimodal datasets, enhancing model transparency, and expanding access to predictive tools across domains. By uniting developments in drug discovery, public health, and fungal research, this review highlights the growing synergy between predictive analytics and life sciences. The integration of these tools into real-world systems offers a pathway to faster therapeutics, smarter diagnostics, and improved ecosystem management.

DOI: https://doi.org/10.54660/.IJMRGE.2022.3.2.825-830

Keywords: Predictive Analytics, Drug Discovery, Fungal Biodiversity, Machine Learning Integration

1. Introduction

Predictive analytics, encompassing machine learning (ML), deep learning (DL), graph neural networks, and statistical modeling, has emerged as a fundamental pillar across biomedical and ecological sciences. Its ability to process and extract insights from large, heterogeneous datasets is reshaping how we discover drugs, monitor diseases, and study complex biological systems (Adans-Dester *et al*., 2020; Abdullahi, 2011) [2, 1]. In the realm of drug discovery, ML-based systems are being integrated throughout the development pipeline from virtual screening and target identification to lead optimization and toxicity prediction. Comprehensive reviews illustrate the rapid adoption of graph neural networks and generative models for molecule design, with some AI-designed compounds already entering early-phase clinical trials (Aerts, 2020; Allegra, 2019) [3, 4].

Similarly, disease surveillance and monitoring have greatly benefited from advances in predictive analytics. Wearable devices, including smartwatches and ECG patches, leverage ML-driven algorithms to detect cardiovascular anomalies, monitor vital signs, and predict adverse events. Recent studies show systems achieving high accuracy in detecting arrhythmias or predicting heart attack risks using CNN-LSTM hybrid models (Chaudhary & Khadabadi, 2012; Manik *et al*., 2018) [10, 24].

The third domain of mycology, particularly macrofungal morphology and fungal biodiversity, has begun to embrace predictive techniques in a manner akin to the other two fields. While still nascent, several studies demonstrate that DL models can classify fungal species from both macroscopic colony images and microscopic slides, reliably reducing identification times by 2–3 days compared to traditional biochemical assays (Manik *et al*., 2018) [24]. Further, whole-genome ML models have successfully predicted fungal lifestyles and ecological traits, enabling biosurveillance applications through phylogenomics and functional inference (Marzana *et al*., 2018; Medina *et al*., 2022; Meyer *et al*., 2020) [26, 27, 28].

Collectively, these three domains reflect a shared trajectory: rich, high-dimensional datasets powering ML/DL approaches to yield actionable insights. But integration across fields is not purely methodological, it flows from converging challenges and opportunities (Hossain, 2021) [19]. Data heterogeneity, for example, is a universal bottleneck: drug discovery relies on chemical libraries, protein interactions, and QSAR data; disease monitoring employs time-series physiological signals and demographic information; mycology spans imaging, environmental parameters, and genomic sequences. These data sources demand preprocessing protocols for normalization, augmentation, and integrity checks, making cross-pollination of best practices beneficial across sectors (Manik *et al*., 2018; Manik *et al*., 2022; Peyclit *et al*., 2021) [23, 24, 30].

Another shared challenge is model interpretability and regulatory alignment. In drug development, ML-generated candidates require mechanistic validation and FDA approval. In healthcare, explainability is increasingly essential for ML-based diagnoses and treatment monitoring. Fungal identification for clinical or ecological endpoints similarly demands transparent models. Emerging efforts in explainable artificial intelligence (XAI) and hybrid modeling frameworks aim to address these needs facilitating trust and enabling human-machine collaboration (Miah *et al*., 2019; Rosa *et al*., 2019) [29].

A major emerging frontier is cross-pollination across domains. For instance, fungi have historically been rich sources of antibiotics and novel metabolites. Predictive models that accurately classify fungal species or deduce functional traits can help prioritize promising isolates for novel drug leads an intersection of mycology and drug discovery. Conversely, methods honed in molecule design or physiological signal analysis can be adapted for fungal imaging or environmental biosurveillance, illustrating a bidirectional exchange of ML innovations (Jonathan *et al*., 2020; Hossain, 2022) [19].

In the broader context, we're observing an accelerated convergence among disciplines driven by both technological and societal factors. Similarly, the global challenge of antimicrobial resistance calls for integrative models that combine genomic data from pathogens, pharmaceutical intervention strategies, and environmental monitoring systems. This review aims to holistically assess predictive analytics across drug discovery, disease surveillance, and mycology, addressing both siloed advancements and synergies. We prioritize literature from 2020 onward to ensure coverage of the latest breakthroughs, particularly in graph-based deep learning, multi-modal sensor fusion, and AI-assisted biodiversity research.

2.0 Predictive Analytics in Drug Discovery

Predictive analytics in drug discovery harnesses machine learning (ML), deep learning (DL), and graph neural networks (GNNs) to revolutionize each phase of the pharmaceutical pipeline from target identification and virtual screening to compound optimization and toxicity prediction (Manik, 2022; Manik *et al*., 2018) [23, 24].

2.1 Target Identification & Hit Discovery

Identifying high-value drug targets remains a key bottleneck. Recent approaches apply ML algorithms to multi-omic, phenotypic, and biomedical graph data. For instance, ML-based knowledge graph techniques leverage heterogeneous biomedical networks to recommend potential drug targets and repurposing candidates reducing reliance on expensive experimental assays (Dongmei *et al*., 2020; Giacobbe *et al*., 2021) [16]. Graph Machine Learning (GML) frameworks have emerged as particularly suited to modeling complex protein–protein and gene–disease interactions, enabling significant improvements in predictive accuracy over traditional methods. Deep learning also supports rapid hit discovery. In one landmark 2020 study, researchers used DL to uncover halicin, a novel antibiotic with a unique mode of action against resistant bacteria an outcome that underscores AI's potential to address antimicrobial resistance (Sitarek *et al*., 2020; Hassan *et al*., 2022) [33, 17]. Meanwhile, AlphaFold 2's breakthrough in protein structure prediction offers a powerful computational scaffold for identifying druggable pockets and modelling target–ligand interactions while expanding the scope of targets amenable to in silico investigation.

2.2 Virtual Screening & Compound Optimization

Virtual screening through ML-enabled models is increasingly used to predict ligand–target affinity at scale, enabling prioritization of active compounds from large chemical libraries. GNNs bear a natural advantage here: they encode molecular geometry and topology directly, showing strong results in binding affinity prediction tasks and significantly outpacing descriptor-based approaches (Andrew *et al*., 2020; Arpaia *et al*., 2013) [8]. Beyond scoring, generative models including Variational Autoencoders (VAEs), Generative Adversarial Networks (GANs), and Junction Tree VAEs have become tools for automated molecule design. For example, JT-VAE systems generate novel molecular structures with optimized binding affinity and drug-like properties by navigating learned latent spaces (Ma *et al*., 2020; Manik, 2022) [23]. Recent efforts integrate reinforcement learning with graph-based generative models to propose compound pairs or combinations that synergize and reduce resistance potential highlighting advanced strategies for network-principled molecule generation (Tobore *et al*., 2019) [34].

2.3 ADMET & Toxicity Prediction

Predicting absorption, distribution, metabolism, excretion, and toxicity (ADMET) early in the pipeline is crucial to reduce late-stage failure. In silico approaches using multi-task deep neural networks (DNNs) have gained traction. For example, the Tox21 Challenge leveraged a multi-task DNN to predict multiple toxicity endpoints achieving cross-validation accuracy above 86% and outperforming single-task models and conventional ML (Tobore *et al*., 2019; Lee *et al*., 2020) [34, 21]

More recently, multi-modal frameworks have combined molecular fingerprints (e.g., Morgan features) with pre-trained SMILES embeddings in a multi-task model to provide explainable predictions for in vitro, in vivo, and clinical toxicity demonstrating an ability to recover interpretable toxicophores and reduce reliance on animal studies. Equivariant GNNs, which respect molecular symmetry, have enhanced drug-induced liver injury (DILI) prediction by encoding 3D structures yielding promising early results (Lee *et al*., 2020) [21].

2.4 Integrating Predictive Pipelines

The true value of predictive analytics lies in **integrated pipelines** that span hit identification, optimization, and ADMET filtering. Firms like Insilico Medicine have reported delivering clinical-stage candidates discovered entirely via AI in under 50 days, blending generative chemistry with ADMET screening (Bulbul *et al*., 2018) [9]. Meanwhile, mega-companies such as GSK and Exscientia are using AI platforms to generate candidate molecules, score them using GNNs, and simulate ADMET profiles dramatically reducing development cost and time (Bulbul *et al*., 2018; Manik, 2022; Manik *et al*., 2018) [23, 24, 9]. Overall, predictive analytics is rapidly evolving from an exploratory tool into a core technology in drug development. The integration of deep generative models, graph-based learning, and multi-modal toxicity prediction marks a shift toward end-to-end AI-driven pipelines. Yet, continued innovation in data standards, model transparency, and domain-specific applications will be essential to fully realize the promise of predictive drug discovery.

3. Disease Surveillance and Monitoring

Predictive analytics has rapidly transformed disease surveillance and monitoring, combining machine learning (ML), wearable devices, and big data to enable early detection, risk stratification, and real-time public health interventions. This section discusses three interrelated applications: (1) cardiovascular health monitoring via wearables, (2) antimicrobial resistance (AMR) surveillance, and (3) epidemic forecasting, highlighting strengths, limitations, and future directions (Ma *et al*., 2020; Manik *et al*., 2022) [23].

3.1 Real-Time Cardiovascular Health Monitoring

Real-time cardiovascular health monitoring utilizes wearable sensors and advanced digital technologies to continuously track vital signs such as heart rate, blood pressure, electrocardiogram (ECG), oxygen saturation, and physical activity. These systems enable early detection of abnormalities like arrhythmias, hypertension, or cardiac arrest, allowing for timely medical intervention. Data collected is often transmitted to healthcare providers via cloud-based platforms, facilitating remote patient management and personalized care (Ma *et al*., 2020; Manik *et al*., 2022; Lee *et al*., 2020) [23, 21]. Integration with artificial intelligence enhances predictive analytics, identifying trends and risk factors. This approach is transforming cardiovascular care by improving patient outcomes, reducing hospital admissions, and supporting preventive strategies for chronic heart conditions. Wearable health devices such as smartwatches, ECG patches, and fitness trackers have revolutionized cardiovascular disease (CVD) monitoring. These devices continuously collect physiological data (e.g., heart rate, accelerometry, skin temperature), which ML models analyze to identify abnormalities (Lee *et al*., 2020; Andrew *et al*., 2020) [21]. Overall, wearable-driven cardiovascular analytics are a maturing field showing early success. The next step involves bridging the gap between promising prototypes and clinically validated deployments through stronger trial design, regulatory efforts, and integration into healthcare systems.

3.2 Surveillance of Antimicrobial Resistance

Preventing future epidemics will require building interoperable infrastructure that integrates wearable data, clinical records, and public health indicators within robust predictive frameworks.

Surveillance of Antimicrobial Resistance (AMR) is the systematic collection, analysis, and dissemination of data on the prevalence and spread of resistance to antimicrobial agents among microbial populations (Andrew *et al*., 2020; Chaudhary & Khadabadi, 2012) [10]. It plays a critical role in public health by identifying emerging resistance patterns, guiding clinical treatment decisions, informing antibiotic stewardship programs, and shaping policy interventions. AMR surveillance involves monitoring resistance in clinical, agricultural, and environmental settings using molecular diagnostics, culture-based methods, and genomic analysis. Global initiatives like WHO's GLASS (Global Antimicrobial Resistance System) aim to standardize data collection and reporting, enabling early detection of threats and coordinated international response to combat AMR (Chaudhary & Khadabadi, 2012; Bulbul *et al*., 2018) [10, 9].

4.0 Integration of Predictive Analytics in Mycology

Predictive analytics is increasingly being applied in mycology both for basic research in fungal biodiversity and practical applications in diagnostics and biosurveillance. Whereas traditional mycological identification relies heavily on expert-led morphological examination and laboratory assays, machine learning (ML) and deep learning (DL) techniques are reshaping the field by automating classification, reducing diagnostic time, and enabling ecological predictions (Aerts, 2020; Allegra, 2019) [3, 4].

4.1 Microscopic & Clinical Diagnostics

Microscopic and Clinical Diagnostics are two essential approaches in identifying and managing diseases. Microscopic diagnostics involve the examination of biological samples (e.g., blood, tissue, or fluid) under a microscope to detect pathogens, cellular abnormalities, or tissue damage (Aminuzzaman *et al*., 2022; Das *et al*., 2016) [6, 12]. Techniques include light microscopy, fluorescence microscopy, and electron microscopy, commonly used in microbiology, histopathology, and parasitology. Clinical diagnostics encompass broader methods such as physical examinations, biochemical tests, imaging, and molecular assays to evaluate symptoms and diagnose diseases. These tests provide critical information on a patient's health status, guiding treatment decisions. Together, these diagnostic tools ensure accurate disease detection and effective healthcare management (Das *et al*., 2021; Bulbul *et al*., 2018) [9, 14].

4.2 Genomic Prediction of Ecological Traits

High-throughput fungal genomics has matured to the point where ML models can predict Genomic prediction of ecological traits involves using genomic data to forecast phenotypic characteristics that influence an organism's interaction with its environment. This approach leverages statistical models and machine learning algorithms to link DNA sequence variation with traits such as drought tolerance, growth rate, nutrient use efficiency, or disease resistance. By incorporating high-throughput genotyping and ecological metadata, researchers can predict how individuals or populations may perform under varying environmental conditions (Das & Aminuzzaman 2017; Rubina *et al*., 2017) [11, 5]. This method enhances conservation strategies, ecosystem management, and crop improvement by enabling selection based on genetic potential rather than observed performance alone, thus accelerating adaptation to climate change and habitat shifts.

4.3 Emerging Integrations & Hybrid Models

Time-lapse imaging, micro-morphology, genomics, and environmental data together point toward holistic, multimodal identification systems. Hybrid image-genomic models combining visual week-1 growth patterns with genome markers to classify fungal pathogens or ecotypes. Knowledge-graph–based AI schemas integrating real-time identification, ecological prevalence, and genomic threat profiles for on-site biosurveillance in agriculture or ecosystem management.

These integrations reflect a broader convergence in predictive analytics, transcending image-only or genome-only silos to deliver more nuanced and actionable fungal intelligence (Aerts, 2020; Allegra, 2019; Hossain, 2021) [3, 4, 19].

The application of predictive analytics in mycology is rapidly expanding—from high-accuracy image-based classification and clinical diagnostics to genomics-driven ecological trait modeling. Yet the field still faces hurdles in data quality, generalizability, and interpretability. Overcoming these through integrated, hybrid approaches and real-world validation will unlock transformative capabilities: near-instant fungal identification, ecological monitoring at scale, and faster clinical decision-making (Hossain, 2021; Aminuzzaman *et al*., 2022; Das *et al*., 2016) [19, 12, 6]. As part of this broader review, the progress in mycology not only complements advances in drug discovery and disease monitoring but also stands to accelerate discovery of fungal bioactive compounds, illuminating paths toward new therapeutics.

5.0 Challenges and Limitations

Even as predictive analytics revolutionize drug discovery, disease monitoring, and mycology, each domain grapples with common and domain-specific barriers. Addressing these is essential for validated, scalable, and ethical application of ML and AI (Miah *et al*., 2019) [29].

5.1 Data Quality, Availability & Heterogeneity

Across all domains, **data heterogeneity** and **limited datasets** pose first-order challenges:

- **Drug Discovery**: Public datasets often suffer from incomplete annotations, batch effects, and skewed target/drug representation (e.g., overemphasis on cancer targets). A recent critical review noted that poor-quality data and non-standardized pipelines are primary barriers to AI adoption in pharmaceutical R&D (Manik, 2021, 2022) [23].
- **Mycology**: Image repositories are limited in taxa coverage, environmental settings, and life stages; genomic and trait datasets suffer sampling bias toward human pathogens or model fungi, limiting generalizable pattern detection (Aminuzzaman & Das, 2017; Das *et al*., 2022) [11, 13].

5.2 Model Interpretability and Trust

High-performing but opaque models' risk being "black boxes" that hinder clinical, regulatory, and ecological adoption:

- In drug discovery, the inability to explain why a model predicts toxicity or efficacy impedes validation and regulatory trust. Explainable AI (XAI) surveys highlight emergent techniques like attention, gradient maps, and rule extraction—but widespread adoption lags (Arpaia *et al*., 2013) [8]
- In healthcare, opaque models raise liability and bias concerns. Advocates emphasize interpretable frameworks like SHAP, counterfactuals, and ensemble transparency to build confidence.
- In mycology, end-users (e.g., ecologists, clinicians) expect transparent species classifications or trait predictions; models using prototype layer attribution or visual saliency are increasingly recommended to gain trust and reproducibility (Das & Aminuzzaman 2017) [11].

5.3 Model Robustness, Validation & Generalizability

Models must prove resilient to real-world variability and attacks:

- **Adversarial threats**: Studies in medicine reveal that small image perturbations or sensor spoofing could misclassify conditions, compromising patient safety.
- **Domain shift**: Models trained in controlled settings often fail under real-world noise, varying lighting, or multi-ethnic data—across drug assays, wearable sensors, and fungal imagery.
- **Prospective validation**: Few ML models undergo longitudinal or prospective validation. Healthcare and mycology models usually report retrospective AUCs without deployment or real-world testing.

Federated evaluation, challenge datasets, and standard benchmarks are needed. Regulations should evolve to encourage field pilots before commercial use. While technological advances in predictive analytics are impressive, real-world impact depends on thoughtful attention to data quality, transparency, robustness, equity, and deployment pathways (Bulbul *et al*., 2018) [9]. Overcoming these challenges calls for multidisciplinary effort, aligned governance, and sustained funding. Doing so will unlock trustworthy, scalable AI across drug discovery, health monitoring, and mycology—and ultimately secure the societal benefits of these domains.

6. Future Directions and Conclusion

Predictive analytics is charting a new era in drug discovery, disease monitoring, and mycology. As the field matures, the next generation of advances will likely focus on integration by building end-to-end, multimodal pipelines and on frameworks that prioritize trustworthiness, scalability, and real-world impact. Below, I outline key future directions before summarizing the review's insights (Das *et al*., 2021; Dongmei *et al*., 2020) [14].

6.1 Toward Integrated, Multimodal Pipelines

The convergence of traditionally isolated pipelines is reshaping biomedical and ecological research. In drug discovery, siloed prediction steps such as binding affinity, ADMET profiling, and target validation are rapidly integrating into streamlined platforms that deliver viable therapeutic candidates within days or weeks. Similar integration is advancing in disease monitoring and mycology. For instance, wearable ECG devices can now trigger cloud-based diagnostic workflows, while macrofungal image recognition systems are being linked to genomic analysis and biosurveillance networks (Das *et al*., 2021; Dongmei *et al*., 2020; Peyclit *et al*., 2021) [14, 30]. However, this convergence presents key challenges. Multimodal data fusion combining chemical, genomic, physiological, and environmental input demands standardized ontologies and interoperable formats. Federated and transfer learning models offer promising pathways for bridging institutional data silos without violating privacy norms. Embedding Explainable AI (XAI) throughout these pipelines is essential to improve interpretability, support model validation, and foster trust among clinical and scientific stakeholders. These integrated systems hold transformative potential for accelerating insights across health and ecological domains (Peyclit *et al*., 2021; Jonathan *et al*., 2020; Hossain, 2022) [19, 30].

6.2 Explainable, Trustworthy, and Ethical AI

Ensuring transparency and trust in AI systems is essential, particularly in healthcare, biosurveillance, and ecological modeling. Hybrid approaches that integrate physical simulations with machine learning offer both predictive strength and interpretability, enabling deeper mechanistic insights, for example, in modeling drug toxicity or fungal trait expression. Techniques such as prototype learning, attention heatmaps, and Grad-CAM visualizations must become standard tools to demystify black-box algorithms, foster trust among clinicians, researchers, and regulators (Jonathan *et al*., 2020; Hossain, 2022; Rosa *et al*., 2019) [19].

To ensure reliability, AI tools in high-stakes domains should undergo rigorous prospective trials rather than relying solely on retrospective validation. In contexts like Software as a Medical Device (SaMD), biosurveillance alerts, or AI-driven crop diagnostics, global alignment with regulatory frameworks such as the EU's AI Act or FDA guidelines is vital for accountability, safety, and ethical compliance (Rosa *et al*., 2019; Giacobbe *et al*., 2021) [16].

Democratizing AI tools and data can bridge equity gaps in science and healthcare. Open-science initiatives like the NIH's model sharing platforms and global pathogen databases pave the way for transparent, inclusive research. Expanding these models to encompass fungal data and multilingual health contexts will amplify global impact. Edge computing and federated learning enable real-time AI deployment in wearable devices and mobile diagnostic apps, providing life-saving insights in underserved and remote communities (Tobore *et al*., 2019; Sitarek *et al*., 2020) [33, 34].

7. Conclusion

The transformative potential of predictive analytics is being realized across three critical domains: drug discovery, disease monitoring, and mycology. From the rapid design of novel compounds using AI-driven molecular generators to real-time cardiovascular disease monitoring via wearable devices, predictive modeling has significantly accelerated both biomedical innovation and diagnostic precision. In mycology, machine learning tools are reshaping the classification and ecological study of macrofungi, while emerging genomic models are revealing novel insights into fungal traits and bioactive compound potential. Despite their distinct applications, these fields share common computational frameworks and challenges, most notably, issues related to data quality, interpretability, model generalizability, and ethical deployment. Through a unified perspective, this review has emphasized the growing intersection of big data and artificial intelligence in shaping the future of healthcare, pharmaceutical development, and fungal biosciences.

Looking ahead, the next wave of progress will hinge on building integrated, multimodal pipelines that unify biological, chemical, genomic, and environmental data for real-world decision-making. Achieving trustworthy, explainable, and ethically governed AI systems will be essential for their adoption in high-stakes clinical, ecological, and regulatory environments. Investment in open, diverse datasets, federated learning infrastructures, and interdisciplinary education will help democratize access and ensure equitable deployment globally. Moreover, fostering cross-domain synergies such as using fungal AI models to support drug discovery or ecosystem biosurveillance could unlock new therapeutic and ecological solutions. As predictive analytics continues to mature, its responsible integration across these domains holds the promise of not only accelerating innovation but also addressing some of the world's most pressing health and environmental challenges.

8. References

1. Abdullahi AA. Trends and challenges of traditional medicine in Africa. Afr J Tradit Complement Altern Med. 2011;8(5S):115-23.
2. Adans-Dester C, Bamberg S, Bertacchi F, *et al*. Can mHealth technology help mitigate the effects of the COVID-19 pandemic? IEEE Open J Eng Med Biol. 2020;1:243-8.
3. Aerts J. Special issue on "Human Health Engineering". Appl Sci. 2020;10(2):564.
4. Allegra M. Antioxidant and anti-inflammatory properties of plants extract. Antioxidants. 2019;8(11):549.
5. Aminuzzaman FM, Das K. Morphological characterization of polypore macro fungi associated with Dalbergia sissoo collected from Bogra district under social forest region of Bangladesh. J Biol Nat. 2017;6(4):199-212.
6. Aminuzzaman FM, Shahi S, Thapa S, Das K. Mushroom diseases and their management: a review. In: Kulshreshtha S, Ukaogo PO, Siddhant, editors. Recent advances in mushroom cultivation technology and its application. Delhi: Bright Sky Publications; 2022. p. 1-27.
7. Liu AC, Patel K, Vunikili RD, Johnson KW, Abdu F, Belman SK, *et al*. Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses. Brief Bioinform. 2020;21(4):1182-95.
8. Arpaia N, Barton GM. The impact of Toll-like receptors on bacterial virulence strategies. Curr Opin Microbiol. 2013;16(1):17-22.
9. Bulbul IJ, Zahir Z, Tanvir A, Alam P. Comparative study of the antimicrobial, minimum inhibitory concentrations

(MIC), cytotoxic and antioxidant activity of methanolic extract of different parts of Phyllanthus acidus (L.) Skeels (family: Euphorbiaceae). World J Pharm Pharm Sci. 2018;8(1):12-57.
10. Chaudhary PH, Khadabadi S. Bombax ceiba Linn.: pharmacognosy, ethnobotany and phyto-pharmacology. Pharmacogn Commun. 2012;2(3):2-9.
11. Das K, Aminuzzaman FM. Morphological and ecological characterization of xylotrophic fungi in mangrove forest regions of Bangladesh. J Adv Biol Biotechnol. 2017;11(4):1-15.
12. Das K, Aminuzzaman FM, Nasim A. Diversity of fleshy macro fungi in mangrove forest regions of Bangladesh. J Biol Nat. 2016;6(4):218-41.
13. Das K, Das SC, Aminuzzaman FM. Environmental and ecological impact of soil microorganisms in plant sciences. J Ecol Nat Resour. 2022;6(2):1-11.
14. Das K, Jhan PK, Das SC, Aminuzzaman FM, Ayim BY. Nanotechnology: past, present and future prospects in crop protection. In: Ahmad F, Sultan M, editors. Technology in agriculture. London: IntechOpen; 2021. p. 1-18.
15. Li D, She X, Calderone R. The antifungal pipeline: the need is established. Are there new compounds? FEMS Yeast Res. 2020;20(4):foaa023.
16. Giacobbe D, Signori A, Del Puente F, Mora S, Carmisciano L, Briano F, *et al*. Early detection of sepsis with machine learning techniques: a brief clinical perspective. Front Med. 2021;8:617416.
17. Hassan J, Barikdar CR, Rozario E, Hossain S, Ahmed MK, Saimon ASM, *et al*. Emerging trends and performance evaluation of eco-friendly construction materials for sustainable urban development. J Mech Civ Ind Eng. 2022;2(2):80-90.
18. Hossain D. A fire protection life safety analysis of multipurpose building [Internet]. 2021 [cited 2023 Nov 10]. Available from: https://digitalcommons.calpoly.edu/fpe_rpt/135/
19. Hossain D. Fire dynamics and heat transfer: advances in flame spread analysis. Open Access Res J Sci Technol. 2022;6(2):70-5.
20. Stokes JM, Yang K, Swanson K, *et al*. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688-702.
21. Lee Y, Chou W, Chien T, Chou P, Yeh Y, Lee H. An app developed for detecting nurse burnouts using the convolutional neural networks in Microsoft Excel: population-based questionnaire study. JMIR Med Inform. 2020;8(5):e16528.
22. Ma S, Chou W, Chien T, Chow J, Yeh Y, Chou P, *et al*. An app for detecting bullying of nurses using convolutional neural networks and web-based computerized adaptive testing: development and usability study. JMIR Mhealth Uhealth. 2020;8(5):e16747.
23. Manik MMTG. An analysis of cervical cancer using the application of AI and machine learning. J Med Health Stud. 2022;3(2):67-76.
24. Manik MMTG, Bhuiyan MMR, Moniruzzaman M, Islam MS, Hossain S, Hossain S. The future of drug discovery utilizing generative AI and big data analytics for accelerating pharmaceutical innovations. Nanotechnol Percept. 2018;14(3):120-35.
25. Manik MMTG, Hossain S, Ahmed MK, Rozario E, Miah MA, Moniruzzaman M, *et al*. Integrating genomic data and machine learning to advance precision oncology and targeted cancer therapies. Nanotechnol Percept. 2022;18(2):219-43.
26. Marzana A, Aminuzzaman FM, Chowdhury MSM, Mohsin SM, Das K. Diversity and ecology of macrofungi in Rangamati of Chittagong Hill Tracts under tropical evergreen and semi-evergreen forest of Bangladesh. Adv Res. 2018;13(5):1-17.
27. Medina N, Alastruey-Izquierdo A, Mercado D, Denning DW, Arathoon E, Rodriguez-Tudela JL. Diagnostic mycology laboratories should have a central role for the management of fungal disease. J Fungi. 2022;8(12):1285.
28. Meyer V, Basenko EY, Benz JP, *et al*. Growing a circular economy with fungal biotechnology: a white paper. Fungal Biol Biotechnol. 2020;7:5.
29. Miah MA, Rozario E, Khair FB, Ahmed MK, Bhuiyan MMR, Manik MTG. Harnessing wearable health data and deep learning algorithms for real-time cardiovascular disease monitoring and prevention. Nanotechnol Percept. 2019;15(3):326-49.
30. Peyclit L, Yousfi H, Rolain JM, Bittar F. Drug repurposing in medical mycology: identification of compounds as potential antifungals to overcome the emergence of multidrug-resistant fungi. Pharmaceuticals. 2021;14(5):488.
31. Börner RA, Kandasamy V, Axelsen AM, Nielsen AT, Bosma EF. Genome editing of lactic acid bacteria: opportunities for food, feed, pharma and biotech. FEMS Microbiol Lett. 2019;366(1):fny291.
32. Rubina H, Aminuzzaman FM, Chowdhury MSM, Das K. Morphological characterization of macro fungi associated with forest tree of National Botanical Garden, Dhaka. J Adv Biol Biotechnol. 2017;11(4):1-18.
33. Sitarek P, Merecz-Sadowska A, Kowalczyk T, Wieczfinska J, Zajdel R, Śliwiński T. Potential synergistic action of bioactive compounds from plant extracts against skin infecting microorganisms. Int J Mol Sci. 2020;21(14):5105.
34. Tobore I, Li J, Yuhang L, Al-Handarish Y, Kandwal A, Nie Z, *et al*. Deep learning intervention for health care challenges: some biomedical domain considerations. JMIR Mhealth Uhealth. 2019;7(8):e11966.